EUCTR2021-004174-64-ES进行中（未招募）1 期
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - ACTION3
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 286
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •- A diagnosis of FSGS confirmed by kidney biopsy. NOTE: The biopsy can have been obtained at any time. Diagnosis of FSGS should be based on light microscopy with supportive findings on either electron microscopy or immunofluorescence analysis (preferably both) and the clinical history and disease course consistent with primary FSGS, genetic FSGS, or FSGS of undetermined cause.
- •- Must be receiving a stable dose of an ARB (irbesartan, losartan, valsartan, candesartan, olmesartan medoxomil, or azilsartan medoxomil) at the maximal tolerated dose and =50% of the maximum recommended dose per the product label for 6 weeks prior to Screening, or willing to transition to this treatment during the Titration and Stabilization period.
- •- If taking corticosteroids, the dosage must be stable for =4 weeks prior to Screening and during the Stabilization period, and patients must have no plan to change their treatment regimen during the study.
- •- If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, or sodium-glucose co-transporter-2 inhibitors, the dose and regimen must be stable for =26 weeks prior to Screening and during the Stabilization period and patients must have no plan to change their treatment regimen during the study.
- •- Urine protein/creatinine ratio (PCR) >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g/day based on 24-hour urine collection during Screening.
- •- Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 at Screening and =25 mL/min/1.73 m2 at the Qualification visit (Week -1).
- •- Seated blood pressure =160/100 mm Hg (mean of 3 values) at Screening and =140/90 mm Hg (mean of 3 values) at the Qualification visit (Week -1).
- •- Body mass index =40 kg/m2 at Screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 263
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •Key Exclusion Criteria:
- •- Has FSGS secondary to another condition.
- •- History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin >8%), or non-fasting blood glucose >10 mmol/L at Screening.
- •- History of lymphoma, leukemia, or any active malignancy within the past 2 years (except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected and with no evidence of metastatic disease).
- •- History of jaundice, active hepatitis, or known hepatobiliary disease (except asymptomatic cholelithiasis).
- •- Documented history of heart failure (New York Heart Association Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening.
- •- Serum potassium levels >5.5 mmol/L at Screening.
- •- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 × upper limit of normal at Screening.
- •- Treatment with immunosuppressant biological drugs, calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 26 weeks prior to Screening
- •- Patients with <80.0% compliance to ARB treatment during the Stabilization Period (Weeks -6 to -1) of the study, as confirmed at the Qualification visit.
研究者
相似试验
招募中
3 期
A Pivotal Phase 3 Study of the Efficacy and Safety of DMX-200 in Patients With focal segmental glomerulosclerosis (FSGS) Who Are Receiving an angiotensin II receptor blocker (ARB)Focal segmental glomerulosclerosis (FSGS)Renal and Urogenital - Kidney diseaseACTRN12622000066785Dimerix Bioscience Pty Ltd286
招募中
1 期
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisFocal segmental glomerulosclerosisMedDRA version: 21.1Level: LLTClassification code: 10016832Term: Focal & segmental glomerulosclerosis Class: 10038359MedDRA version: 21.1Level: PTClassification code: 10067757Term: Focal segmental glomerulosclerosis Class: 100000004857CTIS2023-504597-37-00Dimerix Bioscience Pty Limited326
进行中（未招募）
1 期
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisEUCTR2021-004174-64-DKDimerix Bioscience Pty Ltd286
进行中（未招募）
3 期
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisFocal segmental glomerulosclerosisUrological and Genital DiseasesISRCTN72772236Dimerix Bioscience Pty Ltd286
进行中（未招募）
1 期
A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 given as a single dose (4.8g/day) in subject with acute mild to moderate ulcerative colitis.Subjects who have newly diagnosed or have a diagnosis of relapsing (relapses<to baseline) mild to moderate ulcerative colitis (UC). The original diagnosis of UC (total score of 4-10 on the Ulcerative Colitis Disease Activity Index and with a sigmoidoscopy score of >1 and a Physician Global Assessment of <2). The original diagnosis of UC must be established by sigmoidoscopy, colonoscopy, or barium enema and have compatible histology.EUCTR2004-000733-12-CZShire Pharmaceutical Development Inc255